| Methods |
Double‐blinded, randomized, single‐center trial. Patient evaluations were performed at days 14 and 28 for clinical and laboratory parameters |
| Participants |
Patients with acute attacks of mild to moderate ulcerative colitis. No concomitant medications for UC were allowed (N = 98) |
| Interventions |
Olsalazine, 3 g/day, or placebo, for 28 days |
| Outcomes |
Efficacy was based on evaluations of diarrhea, rectal bleeding, mucorrhea, sigmoidoscopic score, nausea, abdominal tenderness, stool consistency, and global disease severity rating as compared to baseline status |
| Notes |
Abstract |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Double‐blind |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not described |
| Selective reporting (reporting bias) |
Low risk |
Expected outcomes were reported |
| Other bias |
Low risk |
The study appears to be free of other sources of bias |
